The best indicator for Pfizer (PFE)
We backtested 20 indicators across daily, weekly and hourly charts on real Pfizer (PFE) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.
Stochastic
On the daily chart, this is the strongest risk-adjusted edge we found for Pfizer (PFE) over ~54.0 years — trailing buy-and-hold by 3.3% CAGR.
The winner on each chart
Every indicator, ranked
Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.
| # | Indicator | TF | CAGR | Sharpe | Max DD | Win | Trades | vs B&H |
|---|---|---|---|---|---|---|---|---|
| 1 | Stochastic ✓ | Daily | 6.8% | 0.47 | -42.2% | 70.5% | 278 | -3.3% |
| 2 | Bollinger Mean-Reversion ✓ | Daily | 5.3% | 0.43 | -39.5% | 71.0% | 217 | -4.8% |
| 3 | ADX / DMI ✓ | Weekly | 5.6% | 0.42 | -57.3% | 48.7% | 76 | -4.5% |
| 4 | EMA 20/50 Cross ✓ | Weekly | 6.3% | 0.4 | -72.8% | 42.9% | 28 | -3.8% |
| 5 | EMA 50/200 Cross ✓ | Daily | 5.9% | 0.38 | -67.9% | 30.8% | 39 | -4.2% |
| 6 | SMA 50/200 Cross ✓ | Daily | 5.9% | 0.38 | -64.9% | 40.5% | 42 | -4.2% |
| 7 | CCI ✓ | Daily | 5.4% | 0.38 | -47.2% | 71.3% | 258 | -4.7% |
| 8 | Money Flow Index ✓ | Daily | 5.3% | 0.37 | -47.6% | 79.6% | 49 | -4.8% |
| 9 | Bollinger Mean-Reversion ✓ | Weekly | 4.1% | 0.36 | -37.8% | 73.8% | 42 | -6.0% |
| 10 | WaveTrend (8/6/4) ✓ | Daily | 4.9% | 0.34 | -49.1% | 63.8% | 196 | -5.2% |
| 11 | Stochastic ✓ | Weekly | 4.1% | 0.34 | -49.1% | 74.0% | 50 | -6.0% |
| 12 | RSI Mean-Reversion ✓ | Daily | 3.0% | 0.31 | -38.0% | 70.1% | 77 | -7.1% |
| 13 | Williams %R ✓ | Daily | 4.1% | 0.31 | -52.7% | 63.6% | 338 | -6.0% |
| 14 | Donchian Breakout ✓ | Weekly | 3.8% | 0.3 | -62.5% | 45.5% | 44 | -6.3% |
✓ = held up out-of-sample. Hypothetical, costs included. See methodology.
For Pfizer (PFE), Stochastic on the daily timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.
More stock
Get the weekly edge report
The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.